RedHill Biopharma (RDHL) Depreciation & Amortization (CF) (2012 - 2023)

RedHill Biopharma (RDHL) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $595000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Depreciation & Amortization (CF) fell 3.57% year-over-year to $595000.0 in Q2 2023; TTM through Dec 2024 was $595000.0, a 61.51% decrease from a year earlier, with the FY2025 full-year figure at $91000.0, up 193.55% from the prior year.
• Depreciation & Amortization (CF) was $595000.0 for Q2 2023 at RedHill Biopharma, up from $460000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $617000.0 in Q2 2022 and troughed at $226000.0 in Q2 2019.
• A 5-year average of $434000.0 and a median of $467500.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 1209.09% in 2019 and retreated 14.34% in 2023, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $253000.0 in 2019, then jumped by 86.96% to $473000.0 in 2020, then decreased by 5.07% to $449000.0 in 2021, then advanced by 9.35% to $491000.0 in 2022, then gained by 21.18% to $595000.0 in 2023.
• The last three Depreciation & Amortization (CF) figures came in at $595000.0 (Q2 2023), $460000.0 (Q1 2023), and $491000.0 (Q4 2022), per Business Quant data.